Wedbush Securities’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Wedbush Securities’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-985	Closed	-$22K	–	1040
2019 Q2	$22K	Sell	985 -113	-10%	-$5.47K	﹤0.01%	972
2019 Q1	$75K	Hold	1,098	–	–	0.01%	874
2018 Q4	$58K	Buy	1,098 +103	+10%	+$6.58K	0.01%	790
2018 Q3	$68K	Buy	+995	New	+$90.2K	0.01%	858
2017 Q3	–	Sell	-875	Closed	-$41K	–	887
2017 Q2	$41K	Hold	875	–	–	0.01%	810
2017 Q1	$54K	Buy	875 +154	+21%	+$8.95K	0.01%	800
2016 Q4	$43K	Buy	721 +113	+19%	+$7.04K	0.01%	785
2016 Q3	$44K	Buy	608 +187	+44%	+$14.5K	0.01%	796
2016 Q2	$33K	Buy	+421	New	+$80.2K	0.01%	753

Other funds holding SRRA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wedbush Securities's SRRA Position: Q3 2019 in Review

Wedbush Securities sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2019, closing a stake of 985 shares — an estimated $22K sold.

Wedbush Securities first reported a position in SRRA in Q2 2016 and held it in 9 quarters. The position peaked at $75K in Q1 2019. 45 funds tracked by Wall St. Rank hold SRRA as of Q3 2019.

Wedbush Securities reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Wedbush Securities sold 985 Sierra Oncology, Inc. Common Stock shares in Q3 2019, an estimated $22K.
Wedbush Securities first reported a position in Sierra Oncology, Inc. Common Stock in Q2 2016 and held it in 9 quarters.
Wedbush Securities's Sierra Oncology, Inc. Common Stock position peaked at $75K in Q1 2019.
45 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2019.

Based on Wedbush Securities's 13F filing for Q3 2019, filed 17 Oct 2019.